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Discussion
Dr John E. Mayer, Jr (Boston, Mass). First let me congratu-
late Hawkins and colleagues on a clear presentation of important
work. The finding that decellularized homografts do not elicit the
same antibody response as cellular grafts is of significant interest,
particularly for patients who ultimately may require transplanta-
tion. I have found it interesting from a historical and scientific
standpoint how our pendulum has swung from the concept years
ago, when we were told that preserving the viability of cells on
homografts was critical to their long-term function, to the other
end of the spectrum. Now we’re being told that decellularization
will actually be a better process.
I have no specific comments about the antigenicity. And in
some ways I think that the findings are almost what one would
predict. But if one disregards those immunologic considerations, I
wondered about a few things.
First, Dr Hawkins, you have shown that the explanted graft of
homograft material was cellularized, but we don’t really know
what kind of cells they are. In particular, I wondered whether you
had any notions about what the cells on the luminal surface were
like. Have you done any studies on whether they’re true endothelial
cells? One of the fundamental differences between human beings and
most experimental animals is that the ability to reendothelialize seems
to be much less, growing in a few millimeters from either end of the
anastomosis between the artificial material and the true native vessel.
I wondered if you had any information about that.
Second, on the basis of your clinical experience with this
material, could you comment on the effects of the decellularization
process on the structural and hemodynamic performance of the
implanted material?
Dr Hawkins. Actually, we did do some special stains in this
case. I hesitate to make too many conclusions on the basis of a
single patient, but that happens to be all that I have. We did do
stains for endothelial cells and could not find any when we looked
at multiple areas with multiple stains. There is no doubt that there
are cells present. I could conjecture that they’re probably fibro-
blasts. But are they fibroblasts that function? Not only do we need,
at least theoretically, a graft that has normal cells that have grown
into it, we need those normal cells to function to the point that they
participate in protein and collagen turnover. So we don’t really
know the answer to the question of whether these cells are func-
tional. My guess is that they’re probably fibroblasts, and at least in
this case they were not endothelialized at 4 months.
Your second question has to do with my clinical experience
with the hemodynamic function of these decellularized grafts. I
think that a conclusion from the data that I presented today would
be premature. There is no way to know at this point what the
hemodynamic data are of these valved allografts versus standard.
They appear to be equivalent. But are they biomechanically iden-
tical to the human valve? I don’t know. I think that’s the claim, but
I don’t think we really know yet. My own personal opinion is that
the tissue seems—and I stress that this is an anecdotal observa-
tion—to stretch more and to be a bit more elastic than standard
allograft material; however, I believe that the experimental data
from the company and animal data indicate that it’s biomechani-
cally the same.
Dr W. Steves Ring (Dallas, Tex). Do you have any data on
what might be an appropriate third control group? That would be
patients who undergo bypass surgery. Even though you’ve filtered
your blood, what’s the elevation in the flow PRA in that particular
group of patients where you don’t have a homograft?
Dr Hawkins. When we did our original studies back in 1996,
we did a control group of about 14 or 15 children who underwent a
variety of cardiac procedures that did not include implantation of a
homograft but did include bypass with Leukopore-filtered irradiated
blood. Their PRA at 1 month and 3 months was 0. We did not do the
12-month time point, because we considered that it was probably not
ethical to put them through yet another blood sampling for to check a
level that was 0 at 3 months. So we have done such a control group.
I did not include it in this report for the sake of time.
Dr Marshall L. Jacobs (Philadelphia, Pa). Earlier today Dr
Zahid Amin, in discussing acute homograft conduit failure, iden-
tified persistent postoperative fever as a marker or predictive factor
with an odds ratio of 9.1, or something that seemed rather com-
pelling. It’s a simple observation to make. Was there any differ-
ence in the incidence of persistent postoperative fevers in your
decellularized patient group as compared with your historical
control group?
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Dr Hawkins. We did not look at that specifically, Dr Jacobs,
but I think that’s a good question. I’ve always regarded fever in
patients with an allograft as somewhat mysterious. There are
many causes for this. The central question that I think we’re all
asking is about the role of immunologic factors in valve failure.
We know that there’s an immune response, with 100% of the
patients having HLA antibodies; however, not 100% of the
valves fail acutely. Thank goodness. And so the exact role of
immunology in this is difficult to sort out. Perhaps a valve that
is nonimmunogenic will allow us to sort out exactly whether
failure is due to immunology or to all these other factors that Dr
Amin discussed.
Hawkins et al Surgery for Congenital Heart Disease
The Journal of Thoracic and Cardiovascular Surgery ● Volume 126, Number 1 253
CH
D
